Impact Factor
3.96
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.32
1,773 total citations
h5-index
53
h5 depth signal
Cited share
80.4%
349 of 434
Total citations
1,773
Citation footprint
Metric signal
4.30
External metric anchor
Self-citation
1.5%
26 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
440
China
423
Germany
249
Spain
175
United Kingdom
153
Citing Fields of Research
Oncology
545
Cancer & Development
529
Lung Cancer
326
Cancer, Autophagy & Apoptosis
317
Breast Cancer
271
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,981
Articles tracked across the journal lifetime
Indexed publication set
434
349 cited publications
Last 12 months
210
17.5 publications/month
Open access share
100.0%
210 OA publications in the last year
Leading citing country
United States
440 citing publications
Leading citing field
Oncology
545 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v1n1, June 2007-
v1n1, June 2007-
Active Coverage
Research Focus & Classification
Indexed Subjects
Lung Cancer
Oncology
Cancer & Development
Immunology
Cancer, Autophagy & Apoptosis
Breast Cancer
Liver & Colon Cancer
Issuing & Sponsoring Bodies
Contributor
Federation of European Biochemical Societies
Broad Categories
Molecular Biology
Neoplasms
Lung Cancer
Cancer, Autophagy & Apoptosis
Cancer & Development
Immunology
DNA Damage
Genetics & Genomics
MeSH Descriptors
Biomarkers, Tumor.
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1002/1878-0261.70351
Open DOI
Tumour‐proximal deep serum proteomics identifies biomarkers associated with ovarian cancer
Ovarian cancer diagnosis is often delayed due to poorly defined clinical symptoms, underscoring the need for novel biomarkers that enable earlier detection. Protein biomarker discovery in blood samples is analytically challenging using m...
02
DOI 10.1002/1878-0261.70344
Open DOI
Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy
Transcription factors (TFs) are often considered undruggable due to their structural complexity. mRNA technologies can overcome this therapeutic limitation by enabling dynamic protein replacement therapies. Here, we explore the TF activi...
03
DOI 10.1002/1878-0261.70347
Open DOI
Spatial heterogeneity of hotspot mutations and clonal relatedness in ovarian endometrioid carcinoma
Ovarian endometrioid carcinoma (OEC) is a major histotype of endometriosis‐associated ovarian carcinoma, yet the spatial distribution of cancer‐associated mutations and the clonal relatedness of synchronous endometrial and ovarian carcin...
04
DOI 10.1002/1878-0261.70338
Open DOI
Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer
Hereditary nonpolyposis colorectal cancer (HNPCC), usually termed Lynch syndrome (LS), is the most prevalent hereditary colorectal cancer syndrome, yet molecular biomarkers to differentiate nonmalignant from malignant LS cases remain lim...
05
DOI 10.1002/1878-0261.70327
Open DOI
Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer
Ovarian cancer is the most lethal gynecological malignancy, due to late‐stage diagnosis, tumor heterogeneity, and lack of biomarkers for early detection. Extracellular vesicles (EVs) in plasma and ascites offer a minimally invasive sourc...
06
DOI 10.1002/1878-0261.70340
Open DOI
Epigenetics in cancer: from mechanisms to precision medicine
Epigenetics encompasses heritable yet reversible changes in gene expression that occur without alterations to the underlying DNA sequence. Through coordinated regulation of DNA methylation, histone modifications, chromatin remodeling, an...
07
DOI 10.1002/1878-0261.70279
Open DOI
Issue Information
08
DOI 10.1002/1878-0261.70342
Open DOI
Targeting the EpCAM ‐ AXL axis to overcome drug resistance in lung cancer
Drug resistance significantly limits the long‐term effectiveness of targeted therapies in lung cancer. AXL, a receptor tyrosine kinase (RTK), is a well‐established driver of drug resistance in many cancers, including lung cancer. Epithel...
09
DOI 10.1002/1878-0261.70346
Open DOI
Engineering IL ‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy
Adoptive transfer of proinflammatory myeloid cells enhances antitumor T‐cell responses and limits tumor growth in murine models. Previous work identified transcription factors NF‐κB p50 and STAT6 as key regulators whose inactivation enha...
10
DOI 10.1002/1878-0261.70341
Open DOI
Mutant p53 R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation
The tumor suppressor p53 protein is frequently mutated in cancer, conferring oncogenic gain‐of‐function properties. One such mutant, p53 R273H , is known to promote the activation of the PI3K/AKT pathway, but the underlying mechanism is ...
Bibliographical & Catalog Notes
Description based on first issue; title from cover.
Latest issue consulted: Vol. 1, issue 3 (Dec. 2007).
Print issues ceased with v.10 (2016).
Also issued online.